Skip to content

Study · Randomized controlled trial · n = 20 · 2026

9 results

Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study.

Gutierrez de Piñeres V, Tamayo-Torres CS, Ramirez-Cisneros A, Kavelidou M, Stefanakis K, Mantzoros CS

Diabetes, obesity & metabolism24 Nov 2025Cited by 2 (Europe PMC)

PMID41287185 (opens in a new tab)DOI10.1111/dom.70313 (opens in a new tab)PepBankPUB-41287185
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide reduced total body mass versus placebo over 18 days.

    In plain wordsIn adults with type 2 diabetes, liraglutide reduced total body mass versus placebo over 18 days.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal body mass
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    up to 1.8 mg/day · 18 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide reduced total body mass (time × treatment p = 0.04) and lowered absolute and percent android fat (time × treatment p = 0.01 and 0.04), as well as trunk fat mass (time × treatment p = 0.04), with no changes in lean or bone compartments over 18 days.
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled, crossover trial, 20 adults with T2DM received liraglutide (up to 1.8 mg/day) or placebo for 18 days, separated by a washout period.
    Summary · context
    Outcomes were analyzed using linear mixed models with fixed effects for sequence, as well as time, treatment, and interactions.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide lowered absolute android fat versus placebo over 18 days.

    In plain wordsIn adults with type 2 diabetes, liraglutide reduced absolute android fat versus placebo over 18 days.

    Peptide
    Liraglutide
    Outcome
    DecreaseAbsolute android fat
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    up to 1.8 mg/day · 18 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide reduced total body mass (time × treatment p = 0.04) and lowered absolute and percent android fat (time × treatment p = 0.01 and 0.04), as well as trunk fat mass (time × treatment p = 0.04), with no changes in lean or bone compartments over 18 days.
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled, crossover trial, 20 adults with T2DM received liraglutide (up to 1.8 mg/day) or placebo for 18 days, separated by a washout period.
    Summary · context
    Outcomes were analyzed using linear mixed models with fixed effects for sequence, as well as time, treatment, and interactions.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide lowered percent android fat versus placebo over 18 days.

    In plain wordsIn adults with type 2 diabetes, liraglutide reduced android fat percentage versus placebo over 18 days.

    Peptide
    Liraglutide
    Outcome
    DecreasePercent android fat
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    up to 1.8 mg/day · 18 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide reduced total body mass (time × treatment p = 0.04) and lowered absolute and percent android fat (time × treatment p = 0.01 and 0.04), as well as trunk fat mass (time × treatment p = 0.04), with no changes in lean or bone compartments over 18 days.
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled, crossover trial, 20 adults with T2DM received liraglutide (up to 1.8 mg/day) or placebo for 18 days, separated by a washout period.
    Summary · context
    Outcomes were analyzed using linear mixed models with fixed effects for sequence, as well as time, treatment, and interactions.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide lowered trunk fat mass versus placebo over 18 days.

    In plain wordsIn adults with type 2 diabetes, liraglutide reduced trunk fat mass versus placebo over 18 days.

    Peptide
    Liraglutide
    Outcome
    DecreaseTrunk fat mass
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    up to 1.8 mg/day · 18 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide reduced total body mass (time × treatment p = 0.04) and lowered absolute and percent android fat (time × treatment p = 0.01 and 0.04), as well as trunk fat mass (time × treatment p = 0.04), with no changes in lean or bone compartments over 18 days.
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled, crossover trial, 20 adults with T2DM received liraglutide (up to 1.8 mg/day) or placebo for 18 days, separated by a washout period.
    Summary · context
    Outcomes were analyzed using linear mixed models with fixed effects for sequence, as well as time, treatment, and interactions.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, no lean-compartment change was reported with liraglutide versus placebo over 18 days.

    In plain wordsIn adults with type 2 diabetes, no lean-compartment change was reported with liraglutide versus placebo over 18 days.

    Peptide
    Liraglutide
    Outcome
    Not applicableLean compartments
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    up to 1.8 mg/day · 18 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide reduced total body mass (time × treatment p = 0.04) and lowered absolute and percent android fat (time × treatment p = 0.01 and 0.04), as well as trunk fat mass (time × treatment p = 0.04), with no changes in lean or bone compartments over 18 days.
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled, crossover trial, 20 adults with T2DM received liraglutide (up to 1.8 mg/day) or placebo for 18 days, separated by a washout period.
    Summary · context
    Dual-energy X-ray absorptiometry assessed regional fat, lean, and bone compartments.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, no bone-compartment change was reported with liraglutide versus placebo over 18 days.

    In plain wordsIn adults with type 2 diabetes, no bone-compartment change was reported with liraglutide versus placebo over 18 days.

    Peptide
    Liraglutide
    Outcome
    Not applicableBone compartments
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    up to 1.8 mg/day · 18 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide reduced total body mass (time × treatment p = 0.04) and lowered absolute and percent android fat (time × treatment p = 0.01 and 0.04), as well as trunk fat mass (time × treatment p = 0.04), with no changes in lean or bone compartments over 18 days.
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled, crossover trial, 20 adults with T2DM received liraglutide (up to 1.8 mg/day) or placebo for 18 days, separated by a washout period.
    Summary · context
    Dual-energy X-ray absorptiometry assessed regional fat, lean, and bone compartments.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, C-peptide decreased with liraglutide in the 18-day placebo crossover trial (time-by-treatment P=0.026).

    In plain wordsIn adults with type 2 diabetes, C-peptide decreased with liraglutide in the placebo crossover trial, with a significant time-by-treatment interaction.

    Peptide
    Liraglutide
    Outcome
    DecreaseC-peptide
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    up to 1.8 mg/day · 18 daysAs given in this study (human).

    Source sentences

    Summary
    In the liraglutide group, C-peptide decreased while total IGF-1 modestly increased (time × treatment p = 0.026 and 0.002, respectively), with no treatment effects on other MAFI components.
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled, crossover trial, 20 adults with T2DM received liraglutide (up to 1.8 mg/day) or placebo for 18 days, separated by a washout period.
    Summary · context
    Outcomes were analyzed using linear mixed models with fixed effects for sequence, as well as time, treatment, and interactions.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, total IGF-1 modestly increased with liraglutide in the 18-day placebo crossover trial (time-by-treatment P=0.002).

    In plain wordsIn adults with type 2 diabetes, IGF-1 modestly increased with liraglutide in the placebo crossover trial, with a significant time-by-treatment interaction.

    Peptide
    Liraglutide
    Outcome
    IncreaseTotal IGF-1
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    up to 1.8 mg/day · 18 daysAs given in this study (human).

    Source sentences

    Summary
    In the liraglutide group, C-peptide decreased while total IGF-1 modestly increased (time × treatment p = 0.026 and 0.002, respectively), with no treatment effects on other MAFI components.
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled, crossover trial, 20 adults with T2DM received liraglutide (up to 1.8 mg/day) or placebo for 18 days, separated by a washout period.
    Summary · context
    Outcomes were analyzed using linear mixed models with fixed effects for sequence, as well as time, treatment, and interactions.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, no liraglutide treatment effects on other MAFI components were reported in the 18-day placebo crossover trial.

    In plain wordsIn adults with type 2 diabetes, no liraglutide effects on other MAFI components were reported in the placebo crossover trial.

    Peptide
    Liraglutide
    Outcome
    Not applicableOther myostatin-activin-follistatin-IGF-1 components
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    up to 1.8 mg/day · 18 daysAs given in this study (human).

    Source sentences

    Summary
    In the liraglutide group, C-peptide decreased while total IGF-1 modestly increased (time × treatment p = 0.026 and 0.002, respectively), with no treatment effects on other MAFI components.
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled, crossover trial, 20 adults with T2DM received liraglutide (up to 1.8 mg/day) or placebo for 18 days, separated by a washout period.
    Summary · context
    Circulating C-peptide and MAFI components were measured by enzyme-linked immunosorbent assay.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.